Off-Label Use of Atypical Antipsychotics: An Update
Conclusions (1 of 3)
Atypical antipsychotics can improve behavioral symptoms of dementia, although the effect sizes are considered to be small in magnitude.
Several atypical antipsychotics are approved for treating major depressive disorder, and additional members of the class show evidence of efficacy.
- Risperidone (Strength of Evidence = Moderate)
- Ziprasidone (Strength of Evidence = Low)
- Quetiapine XR monotherapy (Strength of Evidence = Moderate)
There is a growing evidence base for the efficacy of individual atypical antipsychotics in treating these disorders:
- Obsessive-compulsive disorder: Risperidone (Strength of Evidence = Moderate)
- Post-traumatic stress disorder (combat-related): Risperidone (Strength of Evidence = Moderate)
- Generalized anxiety disorder: Quetiapine (Strength of Evidence = Moderate)
- Borderline personality disorder: Aripiprazole and Olanzapine (Strength of Evidence = Low)
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | extrapyramidal symptoms | mortality | adverse effects | anorexia nervosa | substance abuse | dementia | MDD | major depressive disorder | OCD | obsessive-compulsive disorder | PTSD | post-traumatic stress disorder | generalized anxiety | borderline personality
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.